- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Insight Molecular Diagnostics Inc (IMDX)
The Insight Molecular Diagnostics share price today is 4.180, view NASDAQ IMDX stock exchange data. Track the latest Insight Molecular Diagnostics share price with real-time updates on IMDX stock performance including market cap, day range, 52-week range and dividend yield. Access IMDX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.865
4.260
52 wk Range
2.330
8.510
IMDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.8654.260
52 wk Range
2.3308.510
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMDX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
8.333
Upside
+99.36%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.333
(+99.36% Upside)
Insight Molecular Diagnostics Inc Earnings Call Summary for Q4/2025
- IMDX submitted GraftAssureDx to FDA and completed $26M offering; stock rose 5.07% aftermarket to $4.35 despite 45% YTD decline.
- Q4 R&D expenses increased due to software development and trials; projected cash burn of $7.5M/quarter in 2026 vs. $6M in 2025.
- Company expanding into heart transplant testing market; needs ~$35M annual revenue for sustainability with low 2026 revenue projected.
- Management expects cash burn decrease in H2 2026 with gradual revenue increase; plans GraftAssure RUO kit launch and transplant center expansion.
- Analyst price targets range $4-$12 (potential 200% upside); Bio-Rad partnership positions company for IVD kit distribution opportunities.
Last Updated: 27-03-2026, 05:04 am
Read Full TranscriptEarnings
Latest Release
26-03-2026
EPS / Forecast
-0.72 / -0.56
Revenue / Forecast
1.14M / --
Compare IMDX to Peers and Sector
Metrics to compare | IMDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −27.6x | −0.5x | |
PEG Ratio | −0.04 | −0.03 | 0.00 | |
Price/Book | −4.3x | 1.6x | 2.6x | |
Price / LTM Sales | 33.2x | 11.7x | 3.2x | |
Upside (Analyst Target) | 125.0% | 68.5% | 47.8% | |
Fair Value Upside | Unlock | −8.2% | 6.7% | Unlock |
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Insight Molecular Diagnostics (IMDX) Share Price Today?
The Insight Molecular Diagnostics share price today is 4.180.
What is the current Insight Molecular Diagnostics (IMDX) share price and day range?
As of 02-05-2026, the Insight Molecular Diagnostics share price is 4.180, with a previous close of 4.010. The share price has ranged from 3.865 to 4.260 today, while the 52-week range spans from 2.330 to 8.510.
What Is the Insight Molecular Diagnostics Market Cap?
As of today, Insight Molecular Diagnostics market cap is 134.460M.
What Is the Insight Molecular Diagnostics (IMDX) Share Price Target?
The average 12-month share price target for Insight Molecular Diagnostics is 8.333, with a high estimate of 12 and a low estimate of 4. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +99.36% Upside potential.
What Is Insight Molecular Diagnostics's Earnings Per Share (TTM)?
The Insight Molecular Diagnostics EPS (TTM) is -1.648.
From a Technical Analysis Perspective, Is IMDX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Stock Exchange Does Insight Molecular Diagnostics Trade On?
Insight Molecular Diagnostics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Insight Molecular Diagnostics?
The stock symbol for Insight Molecular Diagnostics is "IMDX."
How Many Times Has Insight Molecular Diagnostics Stock Split?
Insight Molecular Diagnostics has split 1 times.
How Many Employees Does Insight Molecular Diagnostics Have?
Insight Molecular Diagnostics has 57 employees.
What Is the IMDX Premarket Price?
IMDX's last pre-market stock price is 4.100. The pre-market share volume is 420.000, and the stock has changed by 0.090, or 2.240%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.